Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

O STERN

Showing results (61-70 of 73) with videos related to

Pageof 8
Sort By:
Clinical and Experimental Gastroenterology|December 7, 2016
HCVerso1 and 2: faldaprevir with deleobuvir (BI 207127) and ribavirin for treatment-naïve patients with chronic hepatitis C virus genotype-1b infectionChristoph Sarrazin, Francesco Castelli, Pietro Andreone, et al.
Brain Sciences|June 26, 2025
Catalase Activity in the Brain Is Associated with Recovery from Brain Injury in a Piglet Model of Traumatic Brain InjuryStephanie T Dubrof, Sarah L Schantz, Taylor H LePage, et al.
Hepatology (Baltimore, Md.)|March 19, 2013
Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trialMark S Sulkowski, Marc Bourlière, Jean-Pierre Bronowicki, et al.
Journal of Viral Hepatitis|November 18, 2015
Open-label study of faldaprevir plus peginterferon and ribavirin in hepatitis C virus genotype 1-infected patients who failed placebo plus peginterferon and ribavirinG R Foster, P Ferenci, T Asselah, et al.
The New England Journal of Medicine|August 16, 2013
Faldaprevir and deleobuvir for HCV genotype 1 infectionStefan Zeuzem, Vincent Soriano, Tarik Asselah, et al.
Plos One|December 10, 2015
ITPA Genotypes Predict Anemia but Do Not Affect Virological Response with Interferon-Free Faldaprevir, Deleobuvir, and Ribavirin for HCV InfectionTarik Asselah, Stefan Zeuzem, Vicente Soriano, et al.
Journal of Neurotrauma|July 30, 2025
CMX-2043 Treatment Limits Neural Injury Pathophysiology and Promotes Neurological and Cognitive Recovery in a Pediatric Porcine Traumatic Brain Injury ModelSarah L Schantz, Taylor H LePage, Stephanie T Dubrof, et al.
Gastroenterology|September 20, 2011
Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infectionStefan Zeuzem, Tarik Asselah, Peter Angus, et al.
Antimicrobial Agents and Chemotherapy|December 17, 2014
Efficacy and safety of faldaprevir, deleobuvir, and ribavirin in treatment-naive patients with chronic hepatitis C virus infection and advanced liver fibrosis or cirrhosisStefan Zeuzem, Vicente Soriano, Tarik Asselah, et al.
Antiviral Therapy|April 6, 2013
Faldaprevir (BI 201335), deleobuvir (BI 207127) and ribavirin oral therapy for treatment-naive HCV genotype 1: SOUND-C1 final resultsStefan Zeuzem, Tarik Asselah, Peter Angus, et al.
Pageof 8

Showing results (61-70 of 73) with videos related to

Sort By:
Pageof 8
Clinical and Experimental Gastroenterology|December 7, 2016
HCVerso1 and 2: faldaprevir with deleobuvir (BI 207127) and ribavirin for treatment-naïve patients with chronic hepatitis C virus genotype-1b infectionChristoph Sarrazin, Francesco Castelli, Pietro Andreone, et al.
Brain Sciences|June 26, 2025
Catalase Activity in the Brain Is Associated with Recovery from Brain Injury in a Piglet Model of Traumatic Brain InjuryStephanie T Dubrof, Sarah L Schantz, Taylor H LePage, et al.
Hepatology (Baltimore, Md.)|March 19, 2013
Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trialMark S Sulkowski, Marc Bourlière, Jean-Pierre Bronowicki, et al.
Journal of Viral Hepatitis|November 18, 2015
Open-label study of faldaprevir plus peginterferon and ribavirin in hepatitis C virus genotype 1-infected patients who failed placebo plus peginterferon and ribavirinG R Foster, P Ferenci, T Asselah, et al.
The New England Journal of Medicine|August 16, 2013
Faldaprevir and deleobuvir for HCV genotype 1 infectionStefan Zeuzem, Vincent Soriano, Tarik Asselah, et al.
Plos One|December 10, 2015
ITPA Genotypes Predict Anemia but Do Not Affect Virological Response with Interferon-Free Faldaprevir, Deleobuvir, and Ribavirin for HCV InfectionTarik Asselah, Stefan Zeuzem, Vicente Soriano, et al.
Journal of Neurotrauma|July 30, 2025
CMX-2043 Treatment Limits Neural Injury Pathophysiology and Promotes Neurological and Cognitive Recovery in a Pediatric Porcine Traumatic Brain Injury ModelSarah L Schantz, Taylor H LePage, Stephanie T Dubrof, et al.
Gastroenterology|September 20, 2011
Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infectionStefan Zeuzem, Tarik Asselah, Peter Angus, et al.
Antimicrobial Agents and Chemotherapy|December 17, 2014
Efficacy and safety of faldaprevir, deleobuvir, and ribavirin in treatment-naive patients with chronic hepatitis C virus infection and advanced liver fibrosis or cirrhosisStefan Zeuzem, Vicente Soriano, Tarik Asselah, et al.
Antiviral Therapy|April 6, 2013
Faldaprevir (BI 201335), deleobuvir (BI 207127) and ribavirin oral therapy for treatment-naive HCV genotype 1: SOUND-C1 final resultsStefan Zeuzem, Tarik Asselah, Peter Angus, et al.
Pageof 8